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Abstract

CORTICAL DEVELOPMENT IN FIBROBLAST GROWTH FACTOR 2
KNOCKOUT MICE. Richard X. Lyn-Cook (Sponsored by Flora M. Vaccarino,
M.D., Child Study Center, Yale University School of Medicine, New Haven,
Connecticut)

The pathogenesis of a number of disorders that lead to mental retardation and
cognitive deficiencies are poorly understood. These disorders are often
associated with a decrease in the number of cortical neurons. Fibroblast growth
factor-2 has been strongly implicated in the regulation of cortical volume and cell
number. This experiment is designed to measure the values for the proportion of
proliferative cortical cells (proliferative, P fraction), and those that exit the cell
cycle (quiescent, Q fraction) in FGF-2 knock-out mice. Embryonic days El 1.5,
13.5, and 15.5 were examined covering nearly the entire period of neurogenesis
(E11-E17). The results of this experiment could further elucidate the role of FGF-2
in control of cortical development.
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Introduction
The human cerebral cortex is the evolutionary pinnacle of the mammalian
central nervous system. It comprises about two thirds of the neuronal mass of the
central nervous system and a majority of its synapses (Rakic, 1988). As we
evolved, the cortical surface area and neuronal number increased with associated
increases in intelligence, higher cognitive functioning, and more complex forms
of behavior (Bayer and Altman, 1991).
Despite the differences in neuronal number and cortical volume between
humans and lower mammals, the general pattern of cerebral cortical
development is similar (Rakic, 1988,1995). For this reason, studies in primates
and rodents have proved invaluable in the search for clues to the processes that
govern neurogenesis. These studies have also shed light into the pathogenesis of
clinical disorders that result from aberrant cortical development.
Neuronal progenitor cells arise from the pseudo-stratified ventricular
epithelium (PVE) lining the lateral ventricles in the embryonic telencephalon.
Cortical development occurs in stages divided into neurogenesis, neuronal
migration and neuronal differentiation (Rakic, 1988; Caviness et al, 1995). The
complexity of cortical development makes it quite prone to disruptions at one or
more of its stages. This can result in a host of abnormalities including mild to
severe forms of mental retardation and poor intellectual attainment (BergerSweeney et al, 1997). Disrupted cortical development may lead to microcephaly.
Microcephaly in children has been linked with mental retardation though it is
not an absolute prerequisite for this condition (Martin, 1978; Gross, 1978).
Animal models of microcephaly involving the injection of the antimitotic agent
methylazoxymethanol (MAM) into pregnant rat and mouse dams at the peak of
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neurogenesis have yielded a 50% decrease in cortical thickness in the offspring.
Furthermore, these animals were found to exhibit motor hyperactivity, and
cognitive deficits depending upon the complexity of the task. These animals did
perform normally in other behaviors such as startle, righting, mothering and
visual discrimination, however (Berger-Sweeney et al, 1997)
A 50% decrease in cortical thickness in a rat or mouse may not be
devastating to its survival, whereas a similar finding in humans could result in
severe functional deficits. Congenital anopthalmia and medial geniculate body
malformation, have been linked to a decrease in the size of the visual and
auditory cortices, respectively (Rakic, 1988). Humans have evolved to depend on
higher cortical functions much more for survival.
The basic molecular mechanisms of cortical development are still poorly
understood. In order to gain insight into thepathogenesis and treatment of
disorders stemming from aberrant cortical development, we need to elucidate
the basic mechanisms of and the factors that influence neurogenesis. The
fibroblast growth factor (FGF) family of proteins has been associated with a host
of physiological and pathological processes and has been shown to influence
development (Bikfalvi et al, 1997).

Background and Review of Literature
Basic fibroblast growth factor (FGF2) is a potent mitogenic and
neurotrophic agent that induces proliferation of cells of mesodermal and
neuroectodermal origin (Powell et al, 1991). It is involved with angiogenesis,
smooth muscle growth, wound healing, tissue repair, hematopoiesis and has
been demonstrated to affect survival, proliferation and differentiation of a
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variety of cell types in the central nervous system. (Bikfalvi et al, 1997; Cavanagh
et al, 1997). The biological functions of FGF2 are mediated via binding to high
affinity tyrosine kinase receptors (Partanen et al, 1993).
During neuronal development, FGF2 has been detected in a variety of
species (Bikfalvi et al, 1997) In mice, messenger RNA for FGF2 appears by E9 to
E9.5 (Nurcombe et al, 1993; Ortega et al, 1998). In vitro studies have shown that
FGF2 delays cortical progenitor cell differentiation without affecting cell cycle
parameters (Cavanagh et al, 1997). Earlier in vitro studies demonstrated that
FGF2 stimulated proliferation of cortical neuroectodermal cells (Temple et al,
1995; Gensburger et al, 1987; Vaccarino et al, 1995), maintains the survival of
single cultured neurons (Unsicker et al, 1992), and induces proliferation of
committed neuronal precursor cells (Temple et al, 1995) and mature
oligodendrocytes (Grinspan et al, 1993). Otx2 is one of several homeobox genes
expressed in different regions of the developing mammalian forebrain and is
critically involved in forebrain development. Otx2 mRNA level was enhanced in
cells from rat telencephalon exposed to FGF2 in vitro, suggesting that EGE-2 may
play a role in forebrain neurogenesis (Robel et al, 1995).
In vivo studies have also shown a promising role for FGF-2 in
neurogenesis. Neutralizing antibodies to FGF2 reduced the number of cerebellar
granule and hippocampal precursor neurons in vivo (Tao et al, 1997).
There were several studies using FGF2 knockout mice. One suggested that
FGF2 has a role in the migration and differentiation of neuronal cells, but no
appreciable effect on proliferation in contrast to the in vitro studies (Dono et al,
1998). The knockout mice used in this study are viable and fertile yet their data
suggests that the adult mice have striking defects in cortical morphometry,
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which is not a result of decreased proliferation. Another study by Ortega et al
demonstrated a decrease in neuronal density in the motor cortex of FGF2 -/versus +/+ control (Ortega et al, 1998) in contrast to the Dono results. Data
obtained in our laboratory revealed a 61% decrease in total neuron number in
adult cerebral cortices of FGF2-/- mice (Vaccarino et al, 1999). In addition,
embryonic rats injected in the cerebral ventricles with a single dose of FGF2 at
the beginning of neurogenesis (E15.5) showed a 53% increase in volume and 70%
increase in total number of neurons at E20.5. Similarly microinjected rats assayed
at adulthood showed an 87% increase in total number of neurons (Vaccarino et al,
1999).
The number of progenitor cells, rate of proliferation, and number of
mitotic cycles before terminal differentiation play a significant role in
corticogenesis. The rate of proliferation is measured as length of cell cycle, and
the proportion of dividing cells as growth fraction. Cortical neurogenesis occurs
from embryonic day 11 through early 17 (E11-E17) in the mouse. During this
period, there are approximately 11 cell cycles with a growth fraction of 1.0
(Takahashi et al, 1995,1996). But what effect if any does FGF2 have on these
parameters? Preliminary data from our laboratory demonstrate that FGF2
knockout mice have a decreased proportion of dividing cells (growth fraction)
compared to controls. Conversely, rats microinjected with FGF2 at E15.5
demonstrated an increased growth fraction compared to vehicle microinjected
controls. In both cases the length of the cell cycle between treated and controls
was unchanged (Vaccarino et al, 1999). The reasons for the changes in growth
fraction are not clear, nor do we know about the numbers of proliferative cells
and/or changes in the number of integer cell cycles in FGF2 knockout mice. It is
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possible that the number of proliferating cells is lower to begin with in FGF2
knockout mice, and that fewer proliferating cells require fewer cycles to complete
neurogenesis. It is also possible that the original pool of proliferative neurons is
unchanged and that throughout neurogenesis, the proportion of daughter cells
that elect to re-enter the cell cycle or terminally differentiate is somehow altered
in these knockout mice. It is also possible that both circumstances are true.
The experimental protocol designed by Takahashi et al, 1994, 1996, is a
valuable tool for assessing the kinetics of the proliferative population of the
mouse PVE. It employs a distinct labeling protocol to measure the values for P,
the proportion of proliferating cells that re-enter the cell cycle and Q, the
proportion that terminally differentiate and become quiescent. P+Q=l (see Figure
1. legend and Materials and Methods section for more detail). In this study we
apply a modified version of this method to FGF2 -/- mice to determine
P, Q, and P+Q. The P fraction is 1 and the Q is 0 at the outset of neurogenesis. As
the neuronogenetic interval progresses the P approaches 0, while the Q increases
to 1. The main objective of this present study is to test the effect of FGF2 gene
deletion on the cytokinetic parameters, P and Q. Our hypothesis is that the
absence of FGF2 causes premature exit of neuronal progenitors from the cell cycle
resulting in an early progression of the Q fraction and early exhaustion of the
progenitor population. This can result in a significantly decreased number of
cortical neurons postnatally and in adulthood.

Materials and Methods
Animals
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FGF2 knockout mice were obtained from the McLaughlin Research Institute
(Zhou et al, 1998 ). Fleterozygous (+/-) males were mated with either +/- or -/females. The genotype was established using PCR as described (Zhou et al, 1998 ).
The animals were maintained on a 12 hour (7:00 am to 7:00 pm) light dark
schedule. Conception was ascertained by 9:00 am plug checks with the day of
conception assigned E0.5.

Experimental Design/Analysis
This experimental design was modified from Takahashi et al 1994,1996, (Figure 1).
The purpose of this method was to determine in a two hour cohort of progenitor
cells, the density of the proliferative and quiescent cells (Op+q) and the density of
quiescent cells only (Oq). Two S-phase markers 3[H]thymidine (5mCi/gm body
weight) and the thymidine analog 2-bromodeoxyuridine, (BrdU, 50mg/gm body
weight) are used to distinguish these populations. At 8:00 am a single
intraperitoneal injection of 3[Fi]thymidine is administered to pregnant dams. The
cells that entered the S-phase after the 3[H]thymidine injection incorporate the
3[H]thymidine into the DNA and become labeled. Two hours later, an
intraperitoneal injection of BrdU is administered which is also incorporated into
the DNA during the S-phase. This creates a two hour cohort of 3[H]thymidine only
labeled cells that exited the S-phase in the two hours before injection of the BrdU.
Those 3[H]thymidine labeled cells remaining in the S-phase during BrdU exposure
become doubly labeled with ’[Hjthymidine and BrdU. The cells that entered the Sphase after BrdU injection become singly labeled with BrdU and those cells in the
G1 phase of the cell cycle are unlabelled.

Figure 1. (Adapted from Takahashi et al, 1994) Cells in the S phase were labelled with a single injection of 3[H]thymidme
at 8:00 am (open arrowhead). At 10 am BrdU was injected creating a 2 hour cohort of cells labeled only with 3[H]thymidine (shaded area with perforations). The cells remaining in S phase during BrdU injection are doubly labeled with
3[H]thymidine and BrdU (darkly shaded area). The cells newly entering S phase are singly labeled with BrdU only (light¬
ly shaded). Protocol 1 is used to determine 3p+q or the density of proliferating and quiescent cells belonging to the 2
hour cohort. After the intial BrdU injection, no further injections are done and the animal is sacrificed at a time greater
than the length of the cell cycle (Tc) minus the length of the S phase (Ts). At a time greater than Tc-Ts, the cells of the
original 2 hour cohort will have either re-entered the S phase (p) or left the cell cycle to become quiescent (q). In both of
these cases, the cells of interest are singly labeled with 3[H]thymidine. Thus, the density of 3[H]thymidine cells is equal
to the sum of the density of cells in the proliferative and quiescent fractions of the 2 hour cohort (3p+q). Protocol 2 is
designed to determine the 3q or density of quiescent cells. After the first BrdU injection there are a series of further injec¬
tions 3 hours apart until 1/2 hour before the animal is sacrificed. This corresponds to a time greater than Tc-Ts and
ensures that the cells of the original 2 hour cohort that have re-entered the S-phase become doubly labeled with BrdU
and 3[H]thymidine. The remaining 3[H]thymidine only labeled cells comprise the 3q . Thus, Protocol 1 and 2 yield 3p+q
and 3q, respectively. 3p, and the P and Q fractions are mathematically derived from 3p+q and 3q (see Table 1).
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In Protocol 1, there are no further BrdU injections and the animal is
sacrificed at a time greater than the length of the cell cycle minus the length of
the S-phase (Tc-Ts). The net result is that the 3[H]thymidine singly labeled cells
from Protocol 1 represent the density of both the proliferating and quiescent cells
of that original two hour cohort, or dp+q.
In Protocol 2, after the initial BrdU injection which creates the two hour
cohort of 3[H]thymidine only labeled cells, there are subsequent injections of
BrdU at three hour intervals until half hour before the animal is sacrificed which
is equal to a time greater than Tc-Ts. Similar to Protocol 1 at the time of sacrifice,
the cells of the original two hour cohort have either reentered the cell cycle or
have exited. Those that reenter the cell cycle in Protocol 2 are exposed to the
continued injections of BrdU and become doubly labeled with 3[H]thymidine and
BrdU. These doubly labeled cells are excluded from consideration. Only the
singly labeled cells that exited the cell cycle are counted . These cells represent
dq, the density of quiescent cells of the original two hour cohort..
In both Protocol 1 and Protocol 2, the cells of interest are singly labeled
with 3[H]thymidine and are subsequently counted using light microscopy. The
density of 3Hthymidine labeled cells for Protocol 1 and Protocol 2 in control and
FGF2 -/- animals was determined in sectors encompassing the entire dorsoventral extensionl of the PVE. The sectors were divided into bins measuring
120pm in the anterioposterior dimension, 4pm in the mediolateral dimension,
and 10pm in the inferiosuperior dimension. The bins are parallel to the
ventricular surface with bin 1 starting at the ventricular border. In all cases the
number of cells per bin are counted in ascending bins until the height of the PVE
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is reached (see Figure 2). The number of cells per bin corresponds to a density
measure since the bin is a unit of volume.

Figure 2. Bin Count Diagram

Measurements were conducted in both anterior and posterior regions of the
same brain. Protocol 1 yielded 3p+q, or the density of proliferating and
quiescent cells in all the bins for that area of the PVE. Protocol 2 yielded 3q or the
density of quiescent cells in the same area of a different animal. 3p, the density of
proliferating cells was determined by subtracting 3q from 3p+q (3p=3p+q-3q).

10
Immunocytochemistry and Autoradiography
The embryos were removed by hysterotomy from dams anesthetized with a
combination of ketamine (50 mg/kg) and xylazine (10 mg/kg). The embryos
were measured from head to rump and fixed in 5% acetic acid in 70% ethanol for
2 hours then transferred to 70% ethanol overnight. The embryos were
decapitated and dehydrated in graded ethanol solutions of 85%, 95%, and 100%.
They were then cleared in toluene, embedded in paraffin and sectioned at 10 mm
in the sagittal plane. The sections were stained for BrdU. After
immunocytochemistry, the slides were dipped in a 50:50 mixture of Kodak NTB2
emulsion and 0.5% glycerol in a darkroom and stored at 4°C for 4 weeks. They
were developed using Kodak D-19 developer for 2 minutes, transferred to
distilled water for 15 seconds and then dipped in Kodak general purpose fixer
for three minutes. The sections were counterstained with cresyl violet.
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Results
Determination of Op+q, 9q, and Op
In order to asses the effect of FGF2 gene deletion on the cytokinetic properties of
neuronal precursor proliferation and quiescence in mouse PVE, we followed a
modified protocol of Takahashi et al 1994, 1996, to obtain the P and Q fractions
(see Figure 1. legend). P is equal to the proportion of neuronal precursor cells
that continue to proliferate, while Q is the proportion of cells that exit the cell
cycle to become quiescent throughout the neurogenetic interval.
The present experiment is conducted on brains of embryonic days 11.5,
13.5 and 15.5 (Ell.5, E13.5, E15.5) which correspond to the beginning, middle
and near end of the neurogenetic interval. The cytoarchitecture of the developing
cerebral cortical wall changes throughout the neurogenetic interval. Prior to E14
the PVE, or pseudostratified ventricular epithelium predominates. This area
contains dividing neuronal precursors. In the interval between E13 and E14, the
PVE gives rise to a histologically and functionally separate region called the SPP,
or secondary proliferative population. The SPP is the site of glial precursor cell
proliferation. By E14 the PVE comprises 89% of the proliferative population and
the SPP 11%, while at E16 the proportions are 65% and 35% respectively.
For this experiment, we are only considering the contribution of the PVE
to the P and Q fraction. The first two time points, El 1.5 and E13.5, contain no
appreciable SPP. For the 15.5 time point, it was necessary to histologically
distinguish the two regions and determine the P and Q fraction separately for the
two proliferative populations.
The density of 3Hthymidine only labeled cells was determined in a
120x4x1 Opm sector called a bin, using light microscopy (see Figure 2). Based
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upon the experimental design outlined in Figure 1., two separate protocols were
used to determine two distinct populations of ?Hthymidine labeled cells in the
PVE. In Protocol 1,3Hthymidine positive cells represent the density of P+Q cells
(3p+q), which is the density of proliferating and quiescent cells together. In
Protocol 2,3Hthymidine positive cells represent the density of Q cells (3q) only.
The density of proliferating cells (3p) was obtained by subtracting 3q from 3p+q.
The Proliferative and Quiescent fractions, P and Q respectively, were obtained by
diving 3q by 3p+q and 3p by 3p+q. These formulas are given in Table 1.
Table 1. Determination of dp+q, dq, 3p, P and Q

Protocol 1:

3p+q=density of proliferating and quiescent cells

Protocol 2:

3q=density of quiescent cells

(dp+q and dq were experimentally determined)

3p+q-3q=3p=density of proliferating cells
Q=3q/3p+q=the proportion of cells exiting the cell cycle to
become quiescent
P=3p/3p+q=the proportion of proliferating cells
P+Q=l
(dp, Q, and P were mathematically derived from dp+q and dq)

Counts were done for each of the three time points in both anterior and posterior
regions of the same brain.

Distribution and Density of Proliferating and Quiescent Cells in Control and
FGF2-/- Mice
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Figure 3 shows the distribution of 3p+q, dp and 5q with respect to position in the
developing cortical wall. Each sector was divided into bins and the density of
^Hthymidine labeled cells within each 120x4x10pm bin is shown with respect to
each other. The bins are parallel to the ventricular surface with bin 1 being adjacent
to the ventricular border and bin 9 being near the pial surface (Figure 2). Bins 1-9,
corresponding to the PVE, will be now considered the total volume of our sector for
the purposes of this experiment. The density of cells of the labeled cohort within
this volume 0p+q) at E13.5 in the FGF2 -/- was 72 compared to 92 in the control
which suggests that there is a lower density of cells in the FGF2 -/- mice than in
control. There was a similar finding in the FGF2 -/- at El 1.5 but not at E15.5.
Figure 3 shows the distribution of 5p+q, 5p, and 5q in the posterior sector of
E13.5 PVE. Although Fig. 3 shows that dq is more widely distributed throughout
the PVE in FGF2 -/- mice, there was no overall consistent difference in the dorsoventral distribution between control and FGF2 -/-, when all samples were
considered, both anterior and posterior at the time points considered in this study.

Figure 3. Distribution of ^p+q/ 3p, and 3q cells at E13.5.
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Table 2. summarizes the P and Q data in both anterior and posterior regions of
the same brain in FGF2 -/- and control animals.

Table 2. Cytokinetic Parameters in the PVE for E11.5-E15.5
3p+q is the density of proliferative and quiescent cells in an area which spans the entire height of the PVE
and is 120x4pm in length and depth. 3p is the density of cells remaining in the cell cycle and 3q is the
density of cells exiting the cell cycle. P and Q are proportions of the aforementioned densities. P=3p/3p+q.
Q=3q/3p+q.

A
3p+q

dp

3q

P

Q

Ell.5

1 8

1 0

8

0.56

0.44

El 3.5

1 09
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1 1

67
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0.88

0.12

El 3.5
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El 5.5

72

21
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0.29

0.71

B
FGF2 -/-

Control

POSTERIOR

POSTERIOR

Progression of Q During Neurogenesis
The Q fraction or proportion of cells which have exited the cell cycle proceeds
from 0 at the beginning of neurogenesis and approaches 1 at the end of

15
neurogenesis (Takahashi et al, 1996). Figure 4 illustrates the progression of Q in
anterior and posterior regions of the same brain for both FGF2 -/- and control
Figure 4. Progression of Q During Neurogenesis
Figure 4.A In the anterior region, the Q fraction is intially greater than P. After E13.5, the Q
fraction falls below that of P. 4.B In the posterior region, the Q fraction is greater than P, at all
measured time points during neurogenesis.

A
Progression of Q from El 1.5-El5.5
Anterior Area

11

11.5

13.5

15.5

Age

B
Progression of Q from El 1.5-El 5.5
Posterior Area

16
animals. The data for these graphs is shown in Table 1. Figure 4. A shows that in
the anterior region of the El 1.5, the Q fraction is higher in FGF2-/- than control,
but after E13.5, it falls below that of the control value. This indicates that the
proportion of cells exiting the cell cycle starts out greater than that for the control
at the beginning of neurogenesis, but as neurogenesis proceeds, this proportion
becomes smaller relative to the control. In Figure 4. A, the FGF2-/- Q fraction
approaches 1 at a later time than the control. Similar to Figure 4. A, Figure 4.B
begins with a relatively high value for Q, 0.28 versus 0.12 for control. This
confirms that there is a loss of progenitor cells early in neurogenesis in FGF2-/mice. However, the value for Q for the FGF2 -/- remains higher than that for the
control throughout the neurogenetic interval in this graph. The time when Q
approaches 1 is by definition the end of neurogenesis. This time is reached earlier
for the FGF2-/- than for the control indicating that the absence of FGF2 induces a
premature exhaustion of the proliferative population.

Anterior/Posterior Gradient in the Q Fraction
Figure 5. Progression of Q in Anterior Versus Posterior Regions
Figure 5.A At all time points during the neurogenetic interval, the proportion of cells exiting the
cell cycle or Q, is greater in the anterior than in the posterior regions of fhe same brain in control
mice. 5B. There is no consistent difference between the Q fraction of the anterior and posterior
regions in FGF2 null mice.

A. Control

B. FGF2 -/Anterior/Posterior Gradient in the Q
Fraction

11

11.5

13.5
Age

15.5
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Neurogenesis in the PVE is initiated anteriolaterally and proceeds
posteriomedially (Bayer and Altman, 1991). This well described phenomenon is
the result of a temporospatial gradient in neurogenesis. At all the time points
during the neurogenetic interval, neurogenesis is more advanced in the anterior
region compared to the posterior creating a gradient between anterior and
posterior regions. If the gradient is intact, the measurement of post-mitotic cells or
Q should be greater in the anterior portion of the PVE versus the posterior at the
same point in time due to its relatively more advanced stage of development.
Figure 5.A demonstrates that in control animals, the Q fraction is greater in the
anterior region compared to the posterior. However there is no consistently
elevated Q fraction in the anterior region throughout the neurogenetic interval in
FGF2-/- animals (Figure 5.B), suggesting that the absence of the FGF2 has
disrupted the temporospatial gradient in neurogenesis. The importance of the
gradient is explained in the discussion.

Discussion
Previous studies performed by investigators in this lab have shown that FGF2
plays a significant role in the development of the cerebral cortex (Vaccarino et al,
1999). FGF2 null mice examined at adulthood revealed a nearly 50% decrease in
cortical cell number, while E16 rats injected with FGF2 into the lateral cerebral
ventricles showed an over 80% increase in cortical cell number at adulthood. In
order to understand the mechanism of FGF2 in cortical development, three
different approaches were undertaken. The first approach was directed at
assessing what effect, if any, FGF2 had on progenitor cell survival. Studies
performed in FGF2 microinjected rats showed no change in the amount of cortical
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progenitor apoptosis. Similar studies will be conducted in FGF2 null mice.
The second approach involved determining the length of the cell cycle of
FGF2 null mice versus control to determine if the absence of FGF2 had any effect
on the length of the cell cycle. If the cell cycle length was increased then there
would be fewer cycles within the neurogenetic interval to produce neurons. Cell
cycle data revealed that there was no change in the length of the cell cycle
between FGF2 null and control mice at El 1.5.
The third approach, which was the main objective of this present study,
was an attempt to test the effect of FGF2 gene deletion on the cytokinetic
parameters, P and Q. Our hypothesis was that the absence of FGF2 causes
premature exit of neuronal progenitors from the cell cycle resulting in an early
progression of the Q fraction and early exhaustion of the progenitor population.
This hypothesis predicts that Q should be higher in FGF2 -/- brains at all time
points. At this point in our study, the interpretation of these data is complicated
by the low number of animals which does not allow us to perform statistical
analysis. However our preliminary data do provide some insights regarding the
effect of this gene deletion on these cytokinetic parameters. Comparing anterior
and posterior regions of the same brain had similar statistical limitations but was
useful for the determination of the effect of FGF2 gene deletion on the
temporospatial gradient of neurogenesis.

The Effect FGF2 Gene Deletion on the Progression of the Q Fraction.
In the anterior region (Figure 4.A), the Q fraction for the FGF2 -/- is
elevated above that for the control at El 1.5 but begins to wane after E13.5. The
reason why the Q fraction is not consistently elevated in the FGF2 -/- mice is not
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clear at present and more data are needed to elucidate the cause. It may suggest
that the organism is attempting to compensate for the early decline in the P
fraction toward the middle and end of neurogenesis. The effect of this
compensation is graphically represented by a prolongation of the normal
neurogenetic interval. If this compensation was inadequate, the result could be a
decrease in the volume and total cortical cell number in the adult animal as
demonstrated by previously obtained data.
While the anterior cortical region did not posses a consistent change in the
Q fraction in FGF2-/- mice, in the posterior region we noticed an increase in Q
throughout the neurogenetic interval. Figure 3.B illustrates a left shift in the Q
curve for the FGF-/- at all time points. This indicates that throughout the
neurogenetic interval, the absence of FGF2 has induced neuronal progenitors to
prematurely exit the cell cycle. This also implies an early termination of
neurogenesis which by extrapolation we determined to E17 in the control and
E16 in the FGF2-/-. Shortening the neurogenetic interval is very likely to cause a
severe decrease in the volume and cortical cell number in FGF2 -/- adult mice.
In Figure 4, both anterior and posterior cortical walls have strikingly high
values for Q at El 1.5. The increase in Q fraction at El 1.5 implies a corresponding
decrease in the P fraction. This is consistent with data recently obtained by our lab
showing that at Ell.5 in FGF2 -/- mice there is a decrease in the volume, total cell
number, and number of proliferating cells of the PVE (Raballo, unpublished data).
A lower proportion of proliferating cells in the PVE is expected to cause a
decrease in the amplification of cortical progenitors due to a decrease in
symmetric mitoses. Data obtained in this study also revealed a decrease in the
density (3p+q) of the PVE in El 1.5 and E13.5 FGF2 -/- samples (see Table 2.) All
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these data taken together suggest that the effect of the gene deletion causes both a
decrease in the proliferative pool before or at the very beginning of neurogenesis
and induces early exhaustion of this already depleted pool.

PVE Gradient
It has long been known that neurogenesis proceeds in a non synchronous
pattern in the neuroepithelium. It begins anteriolaterally and proceeds
posteriomedially (Bayer and Altman, 1991) The gradient is dependent upon two
factors, 1. A temporospatial delay in neurogenesis between anteriolateral and
posteriomedial areas, and 2. A stepwise increase in Gx with each successive
integer cell cycle without a change in other cell cycle parameters. At a given time
point during neurogenesis the length of the G1 phase of the cell cycle, TG1 in the
anteriolateral region is greater than TG1 in the posteriomedial region of the same
brain. Alterations in this gradient could lead to aberrant specification of cortical
areas.
Data obtained in this study reveals that with respect to the Q fraction,
which is an direct measurement of the kinetics of corticogenesis, there is an
anterior posterior gradient in the control animals (Figure 5. A) Throughout the
neurogenetic interval, the proportion of cells exiting the cell cycle is greater in the
anterior versus posterior regions. Our data confirm that the progression of Q
reflects the anterior to posterior and lateral to medial gradient of neurogenesis.
In the FGF2 -/- (Figure 5. B), Q is not consistently elevated in the anterior
region throughout the neurogenetic interval. The Q values suggest that there is a
disruption of the neurogenetic gradient in FGF2 -/- mice compared to the control
mice. Previous data suggests that the absence of FGF2 has no effect on the length
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of the cell cycle, therefore the disruption in the gradient would not be caused by
an effect of FGF2 gene deletion on the length of the TG1. The gene deletion may be
disrupting the temporospatial delay causing neurogenesis to proceed more
synchronously across the anterior/posterior dimensions of the PVE. If the
gradient is responsible for creating a map of the cortex in the PVE, then altering
the gradient could lead to aberrant cortical specification. Region specific markers
for somatosensory, motor, or visual cortex could be used to further test this
finding.

Conclusion
In this present study we have shown that the deletion of the gene for
fibroblast growth factor 2 has adverse effects on the cytokinetic parameters P and
Q in a murine model. This current data supports previous data which
demonstrated that in FGF2-/- adult mice there was a 50% decrease in both the
number of cortical neurons and cortical volume.
Our data also demonstrates that early in neurogenesis at Ell.5 in FGF2-/mice, the Q fraction is abnormally elevated in both posterior and anterior
regions. This is consistent with previous data which showed that at El 1.5 there
was a decrease in the number of proliferating cells, and the volume of the PVE,
which further suggests that the decrease in proliferating cells is due to their
premature exit from the cell cycle.
We also found that in FGF2-/- mice at El 1.5 and E13.5, there was a
decrease in the density of the the cells of the proliferative cohort (dp+q) within
thePVE.

23
These data taken together suggest that the effect of the gene deletion
causes both a decrease in the proliferative pool of neuronal progenitors in the
PVE and a premature depletion of this population.
In control animals, we were able to demonstrate the neurogenetic gradient
with respect to the progression of the Q fraction. The gradient was disrupted in
FGF2-/- animals suggesting that FGF2 is necessary for maintenance of the
gradient. Disruptions in the gradient could lead to faulty area specification in the
cortex leading to host of developmental problems.
The insights we have gained from this study have further elucidated the
cytokinetics and molecular mechanisms of cortical development. This will allow
us to better understand the pathophysiology of a host of genetic and congenital
anomalies that may be associated with defects in FGF2 gene or gene product
expression. These defects can have severe effects upon cognitive functioning
leading to mental retardation and developmental delay. From this research and
others similar endeavors we may be able to facilitate the development of novel
treatment strategies.
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